Illumina, Inc. $ILMN Shares Purchased by 180 Wealth Advisors LLC

180 Wealth Advisors LLC raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 35,164 shares of the life sciences company’s stock after buying an additional 2,717 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Illumina were worth $3,355,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ILMN. Corvex Management LP grew its holdings in Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after buying an additional 2,129,449 shares during the last quarter. AQR Capital Management LLC grew its holdings in Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock valued at $165,484,000 after buying an additional 1,662,093 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Illumina by 11,714.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company’s stock valued at $92,184,000 after buying an additional 1,152,048 shares during the last quarter. Brown Advisory Inc. grew its holdings in Illumina by 52.1% during the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company’s stock valued at $230,818,000 after buying an additional 996,589 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Illumina by 51.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock valued at $155,537,000 after buying an additional 667,978 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of a number of analyst reports. Royal Bank Of Canada set a $124.00 target price on Illumina in a report on Tuesday, September 2nd. Robert W. Baird raised their price objective on Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a report on Monday, July 28th. Weiss Ratings restated a “sell (d+)” rating on shares of Illumina in a report on Wednesday, October 8th. Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective on the stock. in a report on Friday, July 11th. Finally, Stephens set a $110.00 price objective on Illumina and gave the stock an “overweight” rating in a report on Monday, August 4th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $115.25.

Illumina Price Performance

Shares of Illumina stock opened at $99.97 on Friday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The stock has a market capitalization of $15.37 billion, a P/E ratio of 12.65, a PEG ratio of 2.40 and a beta of 1.40. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The business’s fifty day moving average price is $98.17 and its 200 day moving average price is $91.30.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter last year, the firm earned $0.36 earnings per share. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.